Sign in
Taking people in United StatesNo phase

Screening relatives of people with dilated cardiomyopathy using mobile heart tracing

Tests a mobile AI heart tracing screen in relatives of people with dilated cardiomyopathy.

Key facts

Who runs it
Lancaster General Hospital
Where
Lancaster, United StatesSee the site
Trial code
Registry title
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
Status
Recruiting
People taking part
150 people, planned
Started
4 Dec 2024
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • Mobile 6L AI-EKG Screening
Record updated
30 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dilated cardiomyopathy not caused by blocked heart arteries, and their adult first-degree relatives. Relatives get a heart check with a mobile ECG.

Age
18 years or older
Sex
Men and women can join
Disease stage
Patients: non-ischemic dilated cardiomyopathy (DCM), with an LVEF of 45% or lower at any time. Relatives: first-degree relatives of a patient with DCM.
Earlier treatment
Relatives must not have had cardiac screening by transthoracic echocardiogram (TTE) before.

Main reasons for not taking part

  • Heart weakness caused by blocked heart arteries or another secondary cause
  • Patient who has already told relatives to get heart screening
  • Relative already told about screening or already screened by TTE
  • Relative already diagnosed with reduced LVEF
  • Relative without a smartphone or tablet with cellular data or Wi-Fi

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Male or female age ≥ 18 years
  • Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient
  • Must have at least one living adult FDR
  • Able to provide informed consent
  • Male or female age ≥ 18 years who are first-degree relatives of patients with DCM
  • Proband has provided informed consent
  • FDR able to provide informed verbal consent
  • Access to a smartphone or digital tablet with cellular data or Wi-Fi access

Who cannot take part

  • Proband has previously informed FDR to undergo cardiac screening
  • Previously informed about cardiac screening or has completed cardiac screening by transthoracic echocardiogram (TTE)
  • Congenital structural heart disease
  • Severe and untreated or untreatable hypertension
  • Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload
  • Ischemic cause of reduced LVEF; evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease; history of acute coronary syndromes (STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-Elevation Myocardial Infarction) or unstable angina) revascularization or ≥75% stenosis of either left main or Left Anterior Descending (LAD) or ≥75% stenosis of 2 major epicardial vessels on angiogram
  • Any secondary cause of reduced LVEF such as pregnancy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
  • Previously diagnosed with reduced LVEF
  • DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination
  • Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy
  • (CPC Participants only) Home address outside of traveling range
  • (CPC Participants only) Home address outside of traveling range

Where in United States

  • Lancaster General HospitalLancaster, United StatesContact: Halle Becker, MPHTaking people

About the trial

What the trial wants to find out

This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.

The group in the trial

  • DCM ScreeningTreatment being tested

    Participants (probands) with dilated cardiomyopathy (DCM) will invite their first-degree relatives (FDR) to participate in DCM screening to examine the impact of an "Artificial Intelligent" (AI) enhanced 6lead (6L) mobile electrocardiogram (EKG) in encouraging FDR of probands with a DCM to obtain appropriate cardiac screening.

    Treatment: Mobile 6L AI-EKG Screening

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dilated Cardiomyopathy Detection Using Artificial Intelligence and Screening With Mobile Technology
Plain-language title
Screening relatives of people with dilated cardiomyopathy using mobile heart tracingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 January 2025